Text Size

Effect of Hemodialysis Membranes on Platelet Count

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Edward Epstein, Staten Island University Hospital
ClinicalTrials.gov Identifier:
NCT01356576
First received: May 13, 2011
Last updated: February 3, 2012
Last verified: February 2012
History of Changes
  Purpose

The purpose of this study is to determine if there is a drop in platelet count after hemodialysis. Hemodialysis membranes are known to activate complement and cause a drop in platelets and sometimes in white blood cells. The investigators are going to study one of the membranes which is the fresenius optiflux to check if it causes a drop in platelets.


Condition
Thrombocytopenia

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Effect of Hemodialysis Membranes on Platelet Count

Resource links provided by NLM:

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Drop in platelet counts [ Time Frame: 90 minutes through hemodialysis and immediately after finishing hemodialysis ] [ Designated as safety issue: No ]

Enrollment: 99
Study Start Date: September 2010
Study Completion Date: September 2011
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients were being selected from the community where undergoing dialysis.

Criteria

Inclusion Criteria:

  • Patients on Hemodialysis for >=6 months

Exclusion Criteria:

  • Hematological Cancers

    • Myelodysplastic syndromes
    • Baseline thrombocytopenia
    • Acute infections (patients on antibiotics)
    • Patients with ITP/TTP
    • HIV
    • Liver disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01356576

Locations
United States, New York
Island Rehabilitative Service
Staten Island, New York, United States, 10305
Sponsors and Collaborators
Staten Island University Hospital
Investigators
Principal Investigator: Edwerd Epstein, M.D. Staten Island University Hospital
  More Information

No publications provided

Responsible Party: Edward Epstein, M.D., Staten Island University Hospital
ClinicalTrials.gov Identifier: NCT01356576     History of Changes
Other Study ID Numbers: 10-039
Study First Received: May 13, 2011
Last Updated: February 3, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Thrombocytopenia
Blood Platelet Disorders
Hematologic Diseases

ClinicalTrials.gov processed this record on June 17, 2013